Our Pricing

Mounjaro Promo Code: £20 Off Your First Order

Published on: June 03, 2026

Searching for a mounjaro promo code uk pharmacy offer? At Cured Pharmacy, new patients save £20 on their first Mounjaro prescription, with prices starting from £124.99. Our UK-registered clinical team provides free online consultations, genuine MHRA-licensed medications, and discreet next-day delivery across the UK.

How to Claim Your Mounjaro Promo Code UK Discount

Claiming your £20 discount on Mounjaro at Cured Pharmacy is straightforward. Simply complete your free online consultation with one of our UK-registered prescribers, and the promotional discount will be automatically applied to your first order at checkout. There are no hidden codes to remember or complex redemption processes.

Your discount applies to all Mounjaro dosage strengths, from the 2.5mg starter dose through to the 15mg maintenance pen. After your prescriber reviews your medical history and confirms suitability, you'll see the reduced price clearly displayed before payment. All Mounjaro pens are genuine UK-licensed KwikPens dispensed by our GPhC-registered pharmacy under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Why Mounjaro Costs Less at Cured Pharmacy

Our transparent pricing model eliminates the markup structures common across UK online pharmacies. We display exact costs upfront—before your consultation—so you know precisely what you'll pay. Unlike many providers, we don't add consultation fees, subscription charges, or hidden delivery costs to your Mounjaro prescription.

By operating exclusively online, we maintain lower overheads than traditional pharmacies whilst still meeting every GPhC regulatory requirement. Our clinical team processes thousands of weight management consultations monthly, allowing us to offer competitive rates without compromising on pharmaceutical standards or prescriber expertise. Every prescription undergoes the same rigorous clinical review regardless of promotional pricing.

Transparent Pricing Across All Dosages

Whether you're prescribed the 2.5mg initiation dose or titrating up to 10mg or 15mg maintenance therapy, our pricing remains consistently lower than typical UK market rates. Your prescriber will determine the appropriate starting dose based on your weight management goals, previous treatment response, and tolerance to GLP-1 medications. Dose escalation follows the licensed MHRA schedule to minimise gastrointestinal side effects whilst optimising efficacy.

How Mounjaro Works for Weight Management

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways [2].

In the SURMOUNT-1 trial, participants receiving the 15mg dose achieved an average body weight reduction of 22.5% over 72 weeks—significantly higher than comparator treatments [1]. The dual receptor activity appears to produce greater metabolic effects than GLP-1 agonism alone, though individual responses vary based on baseline weight, adherence, and lifestyle modifications [3].

Expected Timeline and Results

Most patients begin noticing appetite suppression within the first two weeks of treatment, though significant weight loss typically becomes evident after 8-12 weeks of consistent use. The medication requires gradual dose escalation over 16-20 weeks to reach your target maintenance dose, which helps your body adjust and minimises common side effects like nausea. Clinical trials demonstrated that maximum weight loss occurred between weeks 60-72, emphasising that Mounjaro is a long-term treatment requiring sustained commitment [1].

Mounjaro Promo Code Eligibility and Requirements

The 10% promotional discount applies to first-time Cured Pharmacy patients ordering Mounjaro after completing a successful clinical consultation. To qualify for treatment, you must meet MHRA licensing criteria: a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia.

Your UK prescriber will review your complete medical history, current medications, and any contraindications during the free online assessment. Mounjaro is not suitable for patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Pregnancy, breastfeeding, and plans to conceive within the treatment period are absolute contraindications requiring alternative weight management strategies.

Comparing Weight Loss Treatments Available in the UK

Beyond Mounjaro, several other prescription weight management medications are licensed in the UK, each with distinct mechanisms, efficacy profiles, and administration schedules. Wegovy contains semaglutide, a single GLP-1 receptor agonist administered weekly via subcutaneous injection. Clinical trials showed an average weight reduction of 14.9% over 68 weeks in the STEP-1 trial [4].

Saxenda uses liraglutide, an earlier-generation GLP-1 agonist requiring daily injections rather than weekly administration. Oral medications like Orlistat work through a completely different mechanism—blocking dietary fat absorption in the intestine—and typically produce more modest weight loss of 5-10% when combined with calorie restriction. Mysimba combines naltrexone and bupropion to reduce appetite through central nervous system pathways, offering a non-injectable alternative for patients unsuitable for GLP-1 therapies.

Your prescriber will recommend the most appropriate treatment based on your medical history, weight loss goals, previous treatment responses, and tolerance for injection-based therapies. Many patients prefer weekly injections over daily administration for improved adherence, whilst others prioritise oral medications despite potentially lower efficacy. There is no single 'best' treatment—clinical decisions must be individualised to your circumstances.

Switching Between Weight Loss Medications

If you're currently using Wegovy, Saxenda, or oral weight management medications, transitioning to Mounjaro requires prescriber oversight to ensure safe crossover. GLP-1 receptor agonists should not be used concurrently, and appropriate washout periods may be necessary depending on your current treatment. Your Cured Pharmacy prescriber will create a tailored transition plan if Mounjaro is deemed more suitable for your weight management goals.

What to Expect During Your Mounjaro Treatment Journey

Treatment begins with the 2.5mg dose administered once weekly via subcutaneous injection into your abdomen, thigh, or upper arm. After four weeks, your prescriber will typically increase the dose to 5mg, continuing gradual escalation every four weeks until you reach your optimal maintenance dose—usually 10mg or 15mg depending on efficacy and tolerability [2].

Common side effects during initiation include nausea, diarrhoea, reduced appetite, and occasional vomiting. These gastrointestinal symptoms typically diminish within 4-8 weeks as your body adjusts to each new dose level. Taking Mounjaro with food, staying well-hydrated, and avoiding high-fat meals can help minimise discomfort during the titration phase.

Regular follow-up consultations with your prescriber are essential to monitor progress, adjust dosing, and address any concerns. Weight loss should be gradual and sustained—rapid drops may indicate inadequate nutritional intake requiring dietary review. Mounjaro works most effectively when combined with a reduced-calorie diet and increased physical activity, as demonstrated across all major clinical trials [1][3].

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and are not guaranteed.